How Precisely Can Prostate Cancer Be Managed?

  

Genomics in active surveillance and post-prostatectomy patients: A review of when and how to use effectively

Adedayo Adetunji, Nikit Venishetty, Nita Gombakomba, Karl-Ray Jeune, Matthew Smith, Andrew Winer

Current Urology Reports.2024;[Epub]     CrossRef

Natural history of histologically benign PIRADS 4–5 lesions in multiparametric MRI: Real‐life experience in an academic center

Serdar Madendere, Mert Kilic, Hatice Zoroglu, Ahmet Furkan Sarikaya, Mert Veznikli, Bilgen Coskun, Ayse Armutlu, Ibrahim Kulac, Bengi Gürses, Murat Can Kiremit, Dilek Ertoy Baydar, Abdullah Erdem Canda, Mevlana Derya Balbay, Metin Vural, Yakup Kordan, Tar

The Prostate.2024;[Epub]     CrossRef

Aquaporins as Prognostic Biomarker in Prostate Cancer

Prem Prakash Kushwaha, Shiv Verma, Sanjay Gupta

Cancers.2023; 15(2): 331.     CrossRef

GNL3 and PA2G4 as Prognostic Biomarkers in Prostate Cancer

Shashank Kumar, Mohd Shuaib, Abdullah F. AlAsmari, Faleh Alqahtani, Sanjay Gupta

Cancers.2023; 15(10): 2723.     CrossRef

A review of current clinical biomarkers for prostate cancer: towards personalised and targeted therapy

Ernest Osei, Steph Swanson

Journal of Radiotherapy in Practice.2022; 21(2): 277.     CrossRef

Clinical Proof-of-concept of a Novel Platform Utilizing Biopsy-derived Live Single Cells, Phenotypic Biomarkers, and Machine Learning Toward a Precision Risk Stratification Test for Prostate Cancer Grade Groups 1 and 2 (Gleason 3 + 3 and 3 + 4)

David Albala, Michael S. Manak, Jonathan S. Varsanik, Hani H. Rashid, Vladimir Mouraviev, Stephen M. Zappala, Ene Ette, Naveen Kella, Kimberly M. Rieger-Christ, Grannum R. Sant, Ashok C. Chander

Urology.2019; 124: 198.     CrossRef

Diffusion weighted MRI as an early predictor of tumor response to hypofractionated stereotactic boost for prostate cancer

David Pasquier, Abderraouf Hadj Henni, Alexandre Escande, Emmanuelle Tresch, Nick Reynaert, Olivier Colot, Eric Lartigau, Nacim Betrouni

Scientific Reports.2018;[Epub]     CrossRef

Construction of a set of novel and robust gene expression signatures predicting prostate cancer recurrence

Yanzhi Jiang, Wenjuan Mei, Yan Gu, Xiaozeng Lin, Lizhi He, Hui Zeng, Fengxiang Wei, Xinhong Wan, Huixiang Yang, Pierre Major, Damu Tang

Molecular Oncology.2018; 12(9): 1559.     CrossRef

Live-cell phenotypic-biomarker microfluidic assay for the risk stratification of cancer patients via machine learning

Michael S. Manak, Jonathan S. Varsanik, Brad J. Hogan, Matt J. Whitfield, Wendell R. Su, Nikhil Joshi, Nicolai Steinke, Andrew Min, Delaney Berger, Robert J. Saphirstein, Gauri Dixit, Thiagarajan Meyyappan, Hui-May Chu, Kevin B. Knopf, David M. Albala, Gr

Nature Biomedical Engineering.2018; 2(10): 761.     CrossRef

Wie weit sind die molekularen Marker beim Prostatakarzinom?

Karl Pummer

Journal für Urologie und Urogynäkologie/Schweiz.2017; 19(4): 103.     CrossRef

Wie weit sind die molekularen Marker beim Prostatakarzinom?

Karl Pummer

Journal für Urologie und Urogynäkologie/Österreich.2017; 24(4): 111.     CrossRef

Are We Ready to Use the Omics Strategies for Precision Medicine?

Jayoung Kim

International Neurourology Journal.2016; 20(Suppl 2): S65.     CrossRef